SELLAS Life Sciences Lending Market Update
Data from Interactive Brokers indicates that SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is facing increased borrowing costs for short sellers. As of September 6, 2026, the cost-to-borrow (CTB) fee for SLS shares has reached 10.97%.
Lending Scarcity
With only 35,000 shares reported as available for borrowing, the supply of lendable stock is tightening. A borrow fee in the double digits often signals that institutional lenders are demanding a premium due to high demand from short sellers or a lack of available inventory. Traders should note that this data is specific to Interactive Brokers and reflects the current state of their lending desk, which serves as a proxy for broader market sentiment regarding the stock's borrowability.
Key Takeaways
- Borrow fee for SLS is currently 10.97% APR.
- Available shares for shorting are limited to 35,000 units.
- Tightening supply suggests potential for increased volatility.
The Bottom Line
"The sharp rise in borrow fees for SLS suggests that short sellers are aggressively positioning themselves, creating a potential squeeze risk if the stock price experiences upward momentum."
Signal data sourced from ChartExchange. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.